NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
Apr 04 04:00PM ET
7.47
Dollar change
+0.06
Percentage change
0.81
%
IndexRUT P/E- EPS (ttm)-1.08 Insider Own4.61% Shs Outstand147.77M Perf Week-2.61%
Market Cap1.11B Forward P/E- EPS next Y-0.70 Insider Trans-16.46% Shs Float141.74M Perf Month-3.86%
Income-159.49M PEG- EPS next Q-0.29 Inst Own92.58% Short Float6.69% Perf Quarter20.68%
Sales178.96M P/S6.20 EPS this Y14.71% Inst Trans0.38% Short Ratio5.11 Perf Half Y45.33%
Book/sh1.37 P/B5.45 EPS next Y24.31% ROA-26.57% Short Interest9.49M Perf Year178.73%
Cash/sh1.50 P/C4.99 EPS next 5Y28.67% ROE-62.41% 52W Range2.28 - 9.01 Perf YTD24.60%
Dividend Est.- P/FCF- EPS past 5Y-1.51% ROI-38.50% 52W High-17.09% Beta1.73
Dividend TTM- Quick Ratio2.81 Sales past 5Y17.92% Gross Margin53.95% 52W Low227.63% ATR (14)0.66
Dividend Ex-Date- Current Ratio2.89 EPS Y/Y TTM30.45% Oper. Margin-86.27% RSI (14)45.73 Volatility9.77% 9.20%
Employees619 Debt/Eq1.10 Sales Y/Y TTM5.10% Profit Margin-89.12% Recom1.25 Target Price9.71
Option/ShortYes / Yes LT Debt/Eq1.04 EPS Q/Q52.38% Payout- Rel Volume1.46 Prev Close7.41
Sales Surprise3.06% EPS Surprise10.26% Sales Q/Q3.66% EarningsFeb 11 AMC Avg Volume1.86M Price7.47
SMA20-2.87% SMA50-5.14% SMA20029.92% Trades Volume2,712,584 Change0.81%
Date Action Analyst Rating Change Price Target Change
Mar-21-25Upgrade Goldman Neutral → Buy $9
Jul-05-23Resumed JP Morgan Overweight $15
Jan-05-23Initiated Scotiabank Sector Outperform $15
Dec-21-22Upgrade Piper Sandler Neutral → Overweight $7.50 → $14
Aug-25-22Initiated Credit Suisse Underperform $8
Jun-03-22Initiated Piper Sandler Neutral $7.50
Feb-16-22Reiterated JP Morgan Overweight $75 → $50
Feb-16-22Reiterated Goldman Neutral $54 → $21
Feb-16-22Reiterated BTIG Research Buy $35 → $30
Feb-16-22Reiterated BofA Securities Buy $40 → $32
Mar-20-25 03:06PM
Mar-11-25 08:00AM
Feb-14-25 10:44AM
Feb-12-25 12:00PM
09:56AM
09:40AM Loading…
09:40AM
02:11AM
Feb-11-25 06:30PM
05:35PM
04:45PM
04:05PM
Feb-10-25 07:19AM
Feb-05-25 04:05PM
Feb-04-25 10:28AM
Jan-23-25 05:06PM
06:21AM Loading…
06:21AM
Jan-22-25 04:05PM
Jan-17-25 09:40AM
Jan-16-25 08:33AM
Jan-15-25 10:10AM
Jan-14-25 07:30AM
Jan-07-25 07:30AM
Jan-02-25 04:05PM
Dec-09-24 09:53AM
Dec-07-24 06:30PM
Dec-05-24 07:16AM
Dec-03-24 07:30AM
Nov-29-24 09:40AM
Nov-25-24 01:55PM
Nov-15-24 09:55AM
10:18AM Loading…
Nov-08-24 10:18AM
02:29AM
Nov-07-24 06:30PM
06:15PM
05:11PM
04:05PM
07:30AM
Nov-06-24 07:28AM
Oct-09-24 04:05PM
Oct-04-24 04:35AM
Aug-29-24 07:30AM
Aug-22-24 04:03PM
Aug-01-24 07:00PM
06:20PM
05:23PM
04:05PM
Jul-21-24 06:00AM
Jul-15-24 12:00PM
Jul-11-24 04:05PM
May-31-24 07:30AM
May-29-24 04:05PM
May-25-24 08:30AM
May-24-24 09:58AM
May-23-24 06:00AM
May-16-24 02:30PM
May-08-24 06:43PM
12:19PM
03:54AM
May-07-24 07:30PM
05:47PM
05:40PM
04:37PM
04:05PM
Apr-26-24 10:02AM
Apr-17-24 04:05PM
Apr-02-24 04:05PM
Mar-27-24 04:30PM
08:30AM
Mar-11-24 12:01AM
Feb-22-24 04:05PM
Feb-15-24 10:09AM
06:37AM
Feb-14-24 05:16PM
04:43PM
04:05PM
Feb-13-24 02:23AM
Feb-12-24 09:16AM
Jan-29-24 04:05PM
Dec-27-23 04:05PM
Dec-12-23 05:50AM
Dec-11-23 03:30PM
Dec-09-23 08:30AM
Dec-05-23 07:30AM
Nov-10-23 01:52PM
Nov-09-23 04:17PM
04:05PM
Nov-07-23 07:30AM
Nov-02-23 04:05PM
Oct-26-23 10:02AM
Oct-17-23 07:57AM
Sep-27-23 05:14AM
Sep-13-23 07:30AM
Aug-30-23 04:30PM
Aug-28-23 11:53PM
Aug-24-23 10:29AM
Aug-02-23 05:35PM
04:30PM
04:05PM
Jul-29-23 12:12AM
Jul-19-23 08:52AM
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBINS HARLAN SChief Scientific OfficerMar 24 '25Option Exercise6.321,69810,7311,281,222Mar 26 06:48 PM
ROBINS HARLAN SChief Scientific OfficerMar 24 '25Sale9.001,69815,2821,279,524Mar 26 06:48 PM
Harlan RobinsOfficerMar 24 '25Proposed Sale8.661,69814,705Mar 24 05:45 PM
PISKEL KYLEChief Financial OfficerMar 14 '25Option Exercise6.322,50015,800271,510Mar 17 07:34 PM
GRIFFIN MICHELLE RENEEDirectorMar 13 '25Sale7.1936,291260,93215,394Mar 17 07:33 PM
GRIFFIN MICHELLE RENEEDirectorMar 13 '25Proposed Sale7.1936,291260,861Mar 13 05:28 PM
HERSHBERG ROBERTDirectorMar 12 '25Sale7.5953,000402,27069,690Mar 12 07:48 PM
NEUPERT PETER MDirectorMar 10 '25Option Exercise4.0750,000203,500234,690Mar 12 07:47 PM
NEUPERT PETER MDirectorMar 10 '25Sale7.0510,00070,500224,690Mar 12 07:47 PM
HERSHBERG ROBERTDirectorMar 12 '25Proposed Sale7.5953,000402,270Mar 12 05:30 PM
NEUPERT PETER MDirectorMar 10 '25Proposed Sale7.0510,00070,450Mar 10 02:48 PM
LO FRANCISChief People OfficerMar 05 '25Sale6.9920,875145,845332,846Mar 06 07:22 PM
BOBULSKY SUSANChief Commercial Officer, MRDMar 05 '25Sale6.9826,023181,641347,238Mar 06 07:22 PM
BENZENO SHARONChief Commercial Ofc Imm MedMar 05 '25Sale6.9844,665311,792392,723Mar 06 07:21 PM
PISKEL KYLEChief Financial OfficerMar 05 '25Sale6.9810,32072,072269,010Mar 06 07:20 PM
RUBINSTEIN JULIEPresident and COOMar 05 '25Sale6.9859,505415,540588,249Mar 06 07:19 PM
ROBINS HARLAN SChief Scientific OfficerMar 05 '25Sale6.9996,656675,2191,279,524Mar 06 07:18 PM
ROBINS CHAD MCEO and ChairmanMar 05 '25Sale6.98117,351819,4712,814,350Mar 06 07:17 PM
ROBINS CHAD MCEO and ChairmanMar 06 '25Sale7.64102,218780,9462,959,249Mar 06 07:17 PM
GRIFFIN MICHELLE RENEEDirectorMar 06 '25Sale7.9415,664124,37251,685Mar 06 07:14 PM
MICHELLE GRIFFINDirectorMar 06 '25Proposed Sale7.9415,664124,440Mar 06 04:10 PM
ROBINS CHAD MCEO and ChairmanFeb 19 '25Option Exercise6.32186,0801,176,0262,762,781Feb 21 07:28 PM
ROBINS CHAD MCEO and ChairmanFeb 20 '25Option Exercise6.3299,107626,3562,675,808Feb 21 07:28 PM
ROBINS CHAD MCEO and ChairmanFeb 19 '25Sale8.46186,0801,574,2372,576,701Feb 21 07:28 PM
ROBINS CHAD MCEO and ChairmanFeb 20 '25Sale8.4499,107836,4632,576,701Feb 21 07:28 PM
Chad RobinsOfficerFeb 20 '25Proposed Sale8.3799,107829,526Feb 20 04:02 PM
Chad RobinsOfficerFeb 19 '25Proposed Sale8.37186,0801,557,490Feb 19 04:51 PM
ROBINS CHAD MCEO and ChairmanFeb 18 '25Option Exercise6.32211,1601,334,5312,787,861Feb 18 08:21 PM
ROBINS CHAD MCEO and ChairmanFeb 14 '25Option Exercise6.32158,9211,004,3812,735,622Feb 18 08:21 PM
ROBINS CHAD MCEO and ChairmanFeb 13 '25Option Exercise6.32100,287633,8142,676,988Feb 18 08:21 PM
ROBINS CHAD MCEO and ChairmanFeb 18 '25Sale8.50211,1601,794,8602,576,701Feb 18 08:21 PM
ROBINS CHAD MCEO and ChairmanFeb 14 '25Sale8.46158,9211,344,4722,576,701Feb 18 08:21 PM
ROBINS CHAD MCEO and ChairmanFeb 13 '25Sale8.44100,287846,4222,576,701Feb 18 08:21 PM
Chad RobinsOfficerFeb 18 '25Proposed Sale8.27211,1601,746,293Feb 18 05:35 PM
Chad RobinsOfficerFeb 14 '25Proposed Sale8.33158,9211,323,812Feb 14 04:11 PM
Chad RobinsOfficerFeb 13 '25Proposed Sale8.52100,287854,445Feb 13 05:11 PM
PISKEL KYLEChief Financial OfficerNov 18 '24Sale4.982481,235154,330Nov 19 06:45 PM
BOBULSKY SUSANChief Commercial Officer, MRDOct 08 '24Option Exercise1.985,0009,900253,290Oct 10 05:47 PM
Taylor Stacy LSVP and General CounselAug 22 '24Sale4.5026,922121,079139,365Aug 23 04:27 PM
STACY L TAYLOROfficerAug 22 '24Proposed Sale4.5026,922121,079Aug 22 04:18 PM
Last Close
Apr 04 04:00PM ET
6.46
Dollar change
-0.33
Percentage change
-4.86
%
FTRE Fortrea Holdings Inc daily Stock Chart
Index- P/E- EPS (ttm)-3.45 Insider Own0.36% Shs Outstand90.20M Perf Week-19.55%
Market Cap582.69M Forward P/E7.45 EPS next Y0.87 Insider Trans-5.42% Shs Float89.88M Perf Month-39.57%
Income-308.90M PEG- EPS next Q-0.02 Inst Own104.25% Short Float8.75% Perf Quarter-65.36%
Sales2.70B P/S0.22 EPS this Y49.00% Inst Trans-14.06% Short Ratio4.02 Perf Half Y-66.27%
Book/sh15.19 P/B0.43 EPS next Y76.35% ROA-6.84% Short Interest7.87M Perf Year-83.27%
Cash/sh1.31 P/C4.92 EPS next 5Y60.78% ROE-17.51% 52W Range6.73 - 40.57 Perf YTD-65.36%
Dividend Est.- P/FCF2.46 EPS past 5Y3.94% ROI-12.49% 52W High-84.08% Beta2.00
Dividend TTM- Quick Ratio1.00 Sales past 5Y1.61% Gross Margin16.65% 52W Low-4.01% ATR (14)0.68
Dividend Ex-Date- Current Ratio1.00 EPS Y/Y TTM-9015.30% Oper. Margin-4.15% RSI (14)21.11 Volatility8.59% 6.45%
Employees15500 Debt/Eq0.88 Sales Y/Y TTM-13.27% Profit Margin-11.46% Recom3.00 Target Price11.40
Option/ShortYes / Yes LT Debt/Eq0.81 EPS Q/Q-78.19% Payout- Rel Volume1.50 Prev Close6.79
Sales Surprise-0.89% EPS Surprise-50.66% Sales Q/Q-10.11% EarningsMar 03 BMO Avg Volume1.96M Price6.46
SMA20-25.83% SMA50-47.63% SMA200-66.10% Trades Volume2,933,114 Change-4.86%
Date Action Analyst Rating Change Price Target Change
Dec-11-24Downgrade Citigroup Buy → Neutral $30 → $23
Dec-06-24Downgrade Robert W. Baird Outperform → Neutral $28 → $25
Sep-25-24Downgrade Jefferies Buy → Hold $25 → $21
Aug-08-24Downgrade Evercore ISI Outperform → In-line $31 → $27
Jul-24-24Resumed Barclays Equal Weight $30
Jun-06-24Initiated Goldman Neutral $28
May-29-24Initiated TD Cowen Hold $27
May-28-24Initiated Mizuho Neutral $27
Mar-22-24Initiated Robert W. Baird Neutral $43
Mar-06-24Initiated Deutsche Bank Hold $36
Mar-31-25 08:05AM
Mar-25-25 09:00PM
Mar-20-25 08:07PM
Mar-18-25 05:04AM
Mar-04-25 02:02AM
01:04AM Loading…
01:04AM
Mar-03-25 06:45AM
Feb-21-25 03:33PM
Feb-20-25 07:00AM
Feb-06-25 07:17PM
Jan-30-25 07:00AM
Dec-07-24 05:15AM
Dec-05-24 04:05PM
Nov-26-24 04:15PM
04:15PM
06:45AM Loading…
Nov-12-24 06:45AM
Nov-11-24 12:31PM
Nov-09-24 02:04AM
Nov-08-24 10:15AM
06:30AM
Oct-17-24 07:00AM
Oct-14-24 07:00AM
Aug-13-24 12:58PM
Aug-12-24 07:04PM
07:00AM
Jul-17-24 07:00AM
Jul-11-24 08:42AM
08:00AM
Jun-27-24 07:00AM
Jun-19-24 05:02PM
07:00AM Loading…
Jun-04-24 07:00AM
Jun-03-24 07:00AM
May-30-24 07:01PM
07:00AM
May-21-24 09:48AM
May-17-24 10:15PM
May-16-24 04:05PM
May-15-24 03:56PM
May-14-24 06:43PM
03:01AM
May-13-24 06:50PM
10:52AM
06:30AM
May-06-24 08:22AM
Apr-30-24 01:58PM
Apr-11-24 07:00AM
Mar-12-24 11:24AM
Mar-11-24 06:30AM
06:30AM
Feb-20-24 04:05PM
07:00AM
Jan-29-24 07:00AM
Jan-09-24 04:22PM
Jan-08-24 07:00AM
Jan-05-24 04:53AM
Jan-04-24 08:00AM
Jan-02-24 07:00AM
Dec-13-23 07:00AM
Nov-20-23 07:00AM
Nov-14-23 08:33PM
Nov-13-23 11:07AM
06:30AM
Nov-02-23 07:00AM
Oct-18-23 05:40AM
Oct-17-23 01:35PM
09:05AM
Oct-16-23 08:30PM
Oct-13-23 07:00AM
Oct-11-23 07:00AM
Oct-10-23 07:00AM
Oct-06-23 04:52AM
Sep-15-23 08:45PM
Sep-06-23 11:00AM
11:00AM
Aug-16-23 10:00AM
Aug-15-23 07:03AM
07:03AM
Aug-14-23 07:00AM
Aug-07-23 09:57AM
09:57AM
Jul-20-23 07:00AM
Jul-18-23 07:40AM
Jul-07-23 12:00PM
Jun-28-23 06:08PM
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. It operates under the Clinical Services and Enabling Services Segments. The Clinical Services segment provides services across the clinical pharmacology, clinical development, and other clinical service spectrum utilizing enabling services and technology through multiple delivery models. The Enabling Services segment provides technology solutions directly to customers that streamline complex randomization and optimize the trial drug supply process, while minimizing operational costs and supporting timely and accurate patient dosing. The company was founded on January 31, 2023 and is headquartered in Durham, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hanson James S.General CounselMar 13 '25Option Exercise0.002,998010,473Mar 17 04:37 PM
Hanson James S.General CounselMar 14 '25Sale9.701,0079,7689,466Mar 17 04:37 PM
Morais Mark A.Chief Operating OfficerMar 13 '25Option Exercise0.004,283039,879Mar 17 04:35 PM
Morais Mark A.Chief Operating OfficerMar 14 '25Sale9.701,20711,70838,672Mar 17 04:35 PM
Mcconnell Jill G.Chief Financial OfficerMar 13 '25Option Exercise0.004,283041,677Mar 17 04:33 PM
Mcconnell Jill G.Chief Financial OfficerMar 14 '25Sale9.701,21011,73740,467Mar 17 04:33 PM
Morais Mark A.Chief Operating OfficerMar 12 '25Option Exercise0.00725035,799Mar 14 04:32 PM
Morais Mark A.Chief Operating OfficerMar 13 '25Sale9.932032,01635,596Mar 14 04:32 PM
Mcconnell Jill G.Chief Financial OfficerMar 12 '25Option Exercise0.00935037,655Mar 14 04:31 PM
Mcconnell Jill G.Chief Financial OfficerMar 13 '25Sale9.932612,59237,394Mar 14 04:31 PM
Hanson James S.OfficerMar 14 '25Proposed Sale9.701,0079,766Mar 14 03:40 PM
Morais Mark A.OfficerMar 14 '25Proposed Sale9.701,20711,705Mar 14 03:40 PM
Mcconnell Jill G.OfficerMar 14 '25Proposed Sale9.701,21011,735Mar 14 03:40 PM
Morais Mark A.Chief Operating OfficerMar 11 '25Option Exercise0.001,573035,573Mar 13 04:54 PM
Morais Mark A.Chief Operating OfficerMar 12 '25Sale9.984994,98035,074Mar 13 04:54 PM
Mcconnell Jill G.Chief Financial OfficerMar 11 '25Option Exercise0.002,028037,363Mar 13 04:53 PM
Mcconnell Jill G.Chief Financial OfficerMar 12 '25Sale9.986436,41736,720Mar 13 04:53 PM
Morais Mark A.OfficerMar 13 '25Proposed Sale9.932032,015Mar 13 03:18 PM
Mcconnell Jill G.OfficerMar 13 '25Proposed Sale9.932612,591Mar 13 03:15 PM
Morais Mark A.OfficerMar 12 '25Proposed Sale9.984994,980Mar 12 03:15 PM
Mcconnell Jill G.OfficerMar 12 '25Proposed Sale9.986436,417Mar 12 03:09 PM
ECKERT R ANDREWDirectorFeb 21 '25Option Exercise0.007,282013,636Feb 25 05:12 PM
Morais Mark A.Chief Operating OfficerFeb 11 '25Option Exercise0.001,210034,424Feb 13 05:30 PM
Morais Mark A.Chief Operating OfficerFeb 12 '25Sale14.674246,22034,000Feb 13 05:30 PM
Mcconnell Jill G.Chief Financial OfficerFeb 11 '25Option Exercise0.001,544035,875Feb 13 05:28 PM
Mcconnell Jill G.Chief Financial OfficerFeb 12 '25Sale14.675407,92235,335Feb 13 05:28 PM
Mcconnell Jill G.OfficerFeb 12 '25Proposed Sale14.675407,923Feb 12 03:18 PM
Morais Mark A.OfficerFeb 12 '25Proposed Sale14.674246,221Feb 12 03:15 PM
Mcconnell Jill G.Chief Financial OfficerFeb 07 '25Option Exercise0.001,687034,909Feb 11 04:44 PM
Mcconnell Jill G.Chief Financial OfficerFeb 10 '25Sale14.805788,55434,331Feb 11 04:44 PM
Morais Mark A.Chief Operating OfficerFeb 07 '25Option Exercise0.002,256033,987Feb 11 04:42 PM
Morais Mark A.Chief Operating OfficerFeb 10 '25Sale14.8077311,44033,214Feb 11 04:42 PM
Morais Mark A.OfficerFeb 10 '25Proposed Sale14.8077311,440Feb 10 04:22 PM
Mcconnell Jill G.OfficerFeb 10 '25Proposed Sale14.805788,554Feb 10 04:07 PM
Pike ThomasChief Executive OfficerJan 10 '25Option Exercise0.0040,2200171,136Jan 14 06:08 PM
Pike ThomasChief Executive OfficerJan 13 '25Sale18.0411,268203,275159,868Jan 14 06:08 PM
Pike ThomasOfficerJan 13 '25Proposed Sale18.0411,268203,288Jan 13 03:12 PM
Morais Mark A.Chief Operating OfficerDec 15 '24Option Exercise0.00406031,910Dec 17 05:18 PM
Morais Mark A.Chief Operating OfficerAug 19 '24Option Exercise0.0011,312036,464Aug 20 05:37 PM
Mcconnell Jill G.Chief Financial OfficerAug 19 '24Option Exercise0.0011,312038,194Aug 20 05:36 PM
Pike ThomasChief Executive OfficerAug 19 '24Option Exercise0.00125,6910183,518Aug 20 05:34 PM
Smith David RossDirectorJul 18 '24Option Exercise0.006,35406,354Jul 19 05:24 PM
NEUPERT PETER MDirectorJul 18 '24Option Exercise0.006,354028,350Jul 19 05:23 PM
Pesicka Edward ADirectorJul 18 '24Option Exercise0.006,35406,354Jul 19 05:23 PM
ECKERT R ANDREWDirectorJul 18 '24Option Exercise0.006,35406,354Jul 19 05:22 PM
Ray AmritDirectorJul 18 '24Option Exercise0.006,35406,354Jul 19 05:21 PM
Hanson James S.General CounselJun 12 '24Buy25.302,00050,6007,475Jun 12 06:28 PM
Hanson James S.General CounselJun 03 '24Option Exercise0.007,70607,706Jun 03 07:08 PM
Warren Amanda M.Chief Accounting OfficerJun 03 '24Option Exercise0.003,84206,411Jun 03 07:05 PM
Mcconnell Jill G.Chief Financial OfficerJun 03 '24Option Exercise0.0011,000031,717Jun 03 07:03 PM
Morais Mark A.Chief Operating OfficerJun 03 '24Option Exercise0.0011,000029,406Jun 03 07:01 PM
Pike ThomasChief Executive OfficerMay 29 '24Buy24.8110,000248,06657,827May 30 04:34 PM